Web Exclusives

According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years. Read Article ›

In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies. Read Article ›

The Centers for Medicare & Medicaid Services (CMS) has announced an expansion of coverage for telehealth services for Medicare beneficiaries. To qualify, 2-way real-time interactive communication between providers and patients using both audio and video technology is required. Read Article ›

Remote patient monitoring, in which digital technologies are used to detect changes in vital signs or symptoms, may offer a convenient way to signal the need for a change in management, thereby potentially improving outcomes. Read Article ›

In this discussion, moderated by Niesha Griffith, RPh, MS, FASHP, CPO (interim), a panel of oncology pharmacists discuss the impact of the COVID-19 pandemic on their practices, the increase in the use of new technologies as a result of recent events, and how the influx of patients expected in the coming weeks will affect their daily operations. Read Article ›

Pharmaceutical support and innovation are vital to the effective treatment of patients with cancer. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discussed the importance of maintaining an adequate supply of medicines for patients, and the need for philanthropic programs to ensure patients will be able to continue their medications, even if they lose their health insurance. Read Article ›

As a result of the ongoing COVID-19 pandemic, comprehensive cancer care centers have been tasked with significantly altering their strategies for the delivery of care. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discuss some of the changes that have already been implemented at their centers and future considerations for healthcare systems as they focus on providing safe and effective care on the road to recovery. Read Article ›

Issues surrounding healthcare insurance continue to unfold in light of the recent COVID-19 pandemic. In this discussion, a panel of managed care experts, moderated by Michael Kolodziej, MD, explore strategies for reducing the total cost of care for patients with cancer and addressing the economic and administrative burdens that practices and payers are facing as a result of the crisis. Read Article ›

Addressing the significant physical and psychosocial needs of patients with cancer during the COVID-19 crisis remains a top priority for healthcare providers. In this discussion, moderated by Elizabeth Franklin, PhD, MSW, a panel of specialists explore efforts underway to advocate for patients who are coping with stress, anxiety, and various economic burdens. Read Article ›

On May 1, 2020, the FDA approved a new formulation of daratumumab (Darzalex; Janssen Biotech) and hyaluronidase-fihj (Faspro; Janssen Biotech) for the treatment of adults with newly diagnosed or with relapsed or refractory multiple myeloma. This new formulation allows for the subcutaneous administration of daratumumab as an alternative to its intravenous (IV) administration. The new formulation is approved for the indications previously approved for IV daratumumab. Read Article ›

On April 28, 2020, the FDA accelerated the approval of a new dosing regimen—400 mg every 6 weeks—for pembrolizumab (Keytruda; Merck) for all the 15 indications currently approved by the FDA for adults using this PD-1 inhibitor. The new dosing regimen is a new option in addition to the current dosing regimen of 200 mg every 3 weeks. This is great news for patients, as well as for oncology providers. Read Article ›

On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy. Read Article ›

Page 5 of 12

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: